Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

Discover a study on psoriasis treatment failure, highlighting when to move from topical therapies to systemic care for ...

A groundbreaking technology developed by Heriot-Watt University has received over £475,000 in funding to revolutionize how ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Anti-IL-17A biologics have the greatest odds of achieving and maintaining clear or almost clear skin among patients with psoriasis.

Obesity and the proinflammatory state are sufficiently tied to psoriasis and HS that GLP-1 agonists should be considered within multifaceted care, experts say.

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

Guselkumab is the first IL-23 inhibitor approved for pediatric plaque psoriasis and active psoriatic arthritis, addressing a significant treatment gap. The PROTOSTAR study showed 56% of children on ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, German researchers said in a new study.